Why do we need a new journal in autoimmunity? by D'Cruz, David & Ablamunits, Vitaly
BioMed  Central
Page 1 of 3
(page number not for citation purposes)
Journal of Autoimmune Diseases
Open Access Editorial
Why do we need a new journal in autoimmunity?
David D'Cruz*1 and Vitaly Ablamunits2
Address: 1The Rayne Institute, St Thomas' Hospital, London, UK and 2St. Luke's-Roosevelt Hospital Center and Columbia University, New York, 
NY
Email: David D'Cruz* - david.d'cruz@kcl.ac.uk; Vitaly Ablamunits - ablamunits@excite.com
* Corresponding author    
Abstract
A new online Journal of Autoimmune Diseases is created as an independent open access journal. In
addition to the obvious advantages of the open access, the Journal will practice a double-blind
reviewing of the manuscripts, which means that both the reviewers and the authors remain
anonymous to each other. We believe that such a policy will reduce the influence of personal and
other non-scientific factors on the reviewer's decision making.
Autoimmune diseases are common and can affect virtu-
ally every organ in the body. They range from organ spe-
cific diseases such as thyroiditis or type 1 diabetes to life-
threatening multi-system diseases such as systemic lupus
erythematosus and the systemic vasculitides. Clinicians
from every field of medicine may encounter these patients
and both generalists and specialists need to keep up to
date with clinical and experimental developments in
autoimmunity. The advent of targeted therapies for exam-
ple the anti-TNF-α agents for the treatment of rheumatoid
arthritis exemplify the application of basic science
research that can lead to effective therapies.
Inspired by the publisher, BioMed Central, a group of
enthusiastic professionals gathered to launch the Journal
of Autoimmune Diseases. There are several journals devoted
to autoimmune diseases already, with at least four having
the word "autoimmunity" in the title. In addition, a
number of immunological journals and journals that spe-
cialise in particular diseases publish papers on autoimmu-
nity. So is there a need for yet another journal?
The Editorial Board of Journal of Autoimmune Diseases cer-
tainly thinks so. This Journal is one of the new breed of
online-only journals which are proving extremely success-
ful. But it is not the magic word "internet' that makes the
difference. Two distinct features provided by, BioMed
Central and the Editorial Board offer special advantages to
readers and authors.
Open Access
The aim of publishing is to share information with the
community. Authors are also keen to know that their
work is being read. One of the syndromes of authorship
has been the little card politely requesting a reprint. This
card is sometimes forgotten or filed in the circular filing
cabinet thus inducing considerable guilt both in the
paper's author and the recipient. The era of reprint
requests may be drawing to a close since most of the jour-
nals can now be found on-line. However, the access to a
paper on-line often requires a subscription or a purchase
of an individual article ("pay-per-view"). The high publi-
cation costs of printed journals deprive their publishers of
the generosity of complete free access, but this tends to
limit the dissemination of research. An alternative
approach provided by BioMed Central is to make access
totally free for everybody, as part of their Open Access pol-
icy [1]. It means that Journal of Autoimmune Diseases is uni-
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versally and freely available online to everyone, its
authors retain copyright, and it is archived in internation-
ally recognised free repositories such as PubMed Central
[2]; e-Depot [3]; Potsdam [4] and INIST [5].
Journal of Autoimmune Diseases enables scientists from
countries and institutions with limited funds to read the
same material as wealthier ones [6]. This has become pos-
sible because lower publication costs can be covered by
the authors. The advantage for the authors is also obvious:
access to their work is much more freely available
throughout the world [7].
Double-blinded peer review
The Journal of Autoimmune Diseases aims to provide a high
standard of double-blinded peer review, in which the
reviewer's name is not disclosed to the authors, and the
authors remain anonymous to the reviewers. A few jour-
nals already use this system, so why do we believe that this
will benefit the scientific community?
We have all come across situations where an honest, labo-
rious piece of work was hard to publish. Some journals
reject up to 95% of manuscripts [8], and this includes
good papers. The problem here is that the decision made
by a reviewer is not always based solely on the scientific
merit of the paper. This may cause either of two antiscien-
tific consequences, unfair rejection or unfair acceptance.
It is the nature of human beings that if a reviewer does not
like you personally, a good paper is rejected or additional
possibly unnecessary experiments are required which will
take a year or two. Unfair rejection can occur due to a con-
flict of interest, be it personal or financial. For instance, an
individual may be rejected on the basis of ethnicity [9], so
may his paper be.
An unfair acceptance takes place when the reviewer is
benevolent to a weak paper that has an outstanding name
as the last author. Some authors may successfully exploit
this weakness of a reviewer's human being by placing the
famous name intentionally. This results in a ghost author-
ship of which the celebrity may be unaware! One of us
remembers an anecdotal conversation he heard a few
years ago in one of the universities:
Dorit (a secretary to the Professor): Robert? There is a new
paper of yours I see on Medline. Do you wish me to
update your publication list?
Professor: Who are the other authors?
(Dorit reads 20 last and first names)
Professor: Hm-m-m...I don't know any of these people.
What is the title there?
(Dorit reads the title)
Professor: I don't remember even discussing anything like
that or being consulted...
Dorit: Should I ignore it then?
Professor: Could you print it out for me? I will read it first.
If the paper is good enough...Well, then I'll have nothing
to do but to add it to my list of publications.
What are the remedies then? Two policies that could help
to overcome these difficulties are completely open peer
review and completely anonymous, or double-blind peer
review. In open peer review [10], the reviewers' names are
disclosed to the authors and vice-versa, ensuring account-
ability. Obviously, this might help against unfair rejec-
tions, but not against unfair acceptance. In addition, there
is a danger that younger reviewers will be intimidated and
the political power of the established will be increased [8].
We believe that a double-blinded review process will be
much more effective in helping to avoid rejection of good
papers and acceptance of unsound manuscripts for sub-
jective, political or other non-scientific reasons.
Journal of Autoimmune Diseases
We hope to attract clinical and basic science reports from
leading and innovative authors. We call for established
authors to publish with us in order to be easily accessible
by all other scientists, to stop fighting with the windmills
of the elite journals, to write detailed and clear papers in
the unlimited space provided by internet. We would also
strongly encourage more junior authors who are making
their way in this field to consider publishing high quality
science in the Journal of Autoimmune Diseases – we all need
that important first paper to get going. The Editorial Board
has been carefully selected from leading authorities in
their own fields to help achieve our ambitious aim of
developing a high class international journal that is acces-
sible by all who have internet access and we look forward
to receiving your submissions.
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